Long-term outcomes in pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 63, Issue SUPPL. 162, 2009, Pages 42-44

  Thenappan, T ^a   Palevsky, H I ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; THROMBOXANE SYNTHASE INHIBITOR; UNIPROST; VASODILATOR AGENT; WARFARIN; ANTIHYPERTENSIVE AGENT;

CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FOOD AND DRUG ADMINISTRATION; FRANCE; HEART DEATH; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SUPPLY; OXYGEN THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; ARTICLE; REGISTER; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; REGISTRIES; TREATMENT OUTCOME;

EID: 68349103192     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02128.x     Document Type: Review

References (27)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004 351 : 1655 65.
2. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991 115 : 343 9.
3. Rich S, Dantzker R, Ayres S et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987 107 : 216 23.
4. Sandoval J, Bauerle O, Palomar A et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994 89 : 1733 44.
5. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007 131 : 1917 28.
6. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 173 : 1023 30.
7. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982 2006. Eur Respir J 2007 30 : 1103 10.
8. Fischler M, Speich R, Dorschner L et al. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly. 2008 138 : 371 8.
9. Jing ZC, Xu XQ, Han ZY et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007 132 : 373 9.
10. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner H, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997 112 : 714 21.
11. Fuster V, Steel P, Edwards W et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984 70 : 580.
12. Kawut SM, Horn EM, Berekashvili KK et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005 95 : 199 203.
13. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993 57 : 63 9.
14. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992 327 : 76.
15. Roman A, Rodes-Cabau J, Lara B et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. Med Clin (Barc). 2002 118 : 761 6.
16. Barst R, Rubin L, Long W et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996 334 : 296 301. (Pubitemid 26033085)
17. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 40 : 780 8.
18. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002 106 : 1477 82.
19. Barst RJ, Galie N, Naeije R et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J 2006 28 : 1195 203.
20. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005 25 : 244 9.
21. Sitbon O, McLaughlin VV, Badesch DB et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005 60 : 1025 30.
22. Thenappan T, Shah SJ, Rich S, Archer SL, Gomberg-Maitland M. Survival Of Patients With Pulmonary Arterial Hypertension (PAH) In The Current Era: Validation Of The National Institute Of Health (NIH) Risk Stratification Equation. Chest 2007 132 : 487.
23. Macchia A, Marchioli R, Marfisi R et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007 153 : 1037 47.
24. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009 30 : 394 403.
25. Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008 5 : 617 22.
26. Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 117 : 3010 9.
27. Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008 149 : 521 30.